DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ventolin HFA (Albuterol Sulfate HFA Inhalation) - Published Studies


Ventolin HFA Related Published Studies

Well-designed clinical trials related to Ventolin HFA (Albuterol HFA)

Repeat dosing of albuterol via metered-dose inhaler in infants with acute obstructive airway disease: a randomized controlled safety trial. [2010.03]

Safety of daily albuterol in infants with a history of bronchospasm: a multi-center placebo controlled trial. [2009.07.16]

A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects. [2008.09]

Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma. [2007.12]

An evaluation of levalbuterol HFA in the prevention of exercise-induced bronchospasm. [2007.11]

Dose-response to salbutamol via a novel palm sized nebuliser (Aerodose Inhaler), conventional nebuliser (Pari LC Plus) and metered dose inhaler (Ventolin Evohaler) in moderate to severe asthmatics. [2005.01]

Comparison of the bronchodilating effects of formoterol and albuterol delivered by hydrofluoroalkane pressurized metered-dose inhaler. [2005]

Efficacy response of inhaled HFA-albuterol delivered via the breath-actuated Autohaler inhalation device is comparable to dose in patients with asthma. [2003]

A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients. [2002.05]

Albuterol HFA is as effective as albuterol CFC in preventing exercise-induced bronchoconstriction. [2002.05]

Switching from Ventolin CFC to Ventolin HFA is well tolerated and effective in patients with asthma. [2001.03]

Comparable bronchodilation with hydrofluoroalkane-134a (HFA) albuterol and chlorofluorocarbons-11/12 (CFC) albuterol in children with asthma. [2000.12]

Clinical comparability of ventolin formulated with hydrofluoroalkane or conventional chlorofluorocarbon propellants in children with asthma. [2000.12]

Safety of long-term treatment with HFA albuterol. [1999.04]

Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol. [1999]

Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma. [1998.12]

Proventil HFA and ventolin have similar safety profiles during regular use. [1998.02]

Proventil HFA provides bronchodilation comparable to ventolin over 12 weeks of regular use in asthmatics. [1998.02]

Proventil HFA provides protection from exercise-induced bronchoconstriction comparable to proventil and ventolin. [1997.07]

Well-designed clinical trials possibly related to Ventolin HFA (Albuterol HFA)

Predictors of response to tiotropium versus salmeterol in asthmatic adults. [2013]

Comparative lung bioavailability of fluticasone/salmeterol via a breath-actuated spacer and conventional plastic spacers. [2011.04]

Systemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacer. [2010.06]

A novel breath-actuated integrated vortex spacer device increases relative lung bioavailability of fluticasone/salmeterol in combination. [2009.08]

Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life. [2009.04]

Inhaled corticosteroids as additional treatment in alpha-1-antitrypsin-deficiency-related COPD. [2008]

A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. [2007.06]

A comparative study of patients' preferences and sensory perceptions of three forms of inhalers among Thai asthma and COPD patients. [2007.06]

Efficacy of beclomethasone dipropionate HFA 200 microg once daily in chronic obstructive pulmonary disease and bronchial asthma. [2007.05]

Inhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthma. [2007.03]

Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study. [2006.11]

Inhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthma. [2006.07.25]

Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. [2006.01]

Fluticasone Propionate HFA-134a Pressurized Metered-Dose Inhaler in Adolescents and Adults with Moderate to Severe Asthma. [2005.12]

The effect of reducing the fine-particle mass of salmeterol from metered-dose inhalers on bronchodilatation and bronchoprotection against methacholine challenge: a randomized, placebo-controlled, double-blind, crossover study. [2005.07]

Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. [2005.07]

Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. [2005.07]

Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects. [2005.04]

Salmeterol HFA is as effective as salmeterol CFC in children and adults with persistent asthma. [2005.04]

Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma. [2004]

Efficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment. [2003.09]

Clinical equivalence between salbutamol hydrofluoroalkane pMDI and salbutamol Turbuhaler at the same cumulative microgram doses in paediatric patients. [2002.11]

Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone. [2002.06]

In vivo lung deposition of hollow porous particles from a pressurized metered dose inhaler. [2002.03]

Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients. [2001.11]

Asthma stability after oral prednisone: a clinical model for comparing inhaled steroid potency. [2001.10.01]

Comparative in vivo lung delivery of hydrofluoroalkane-salbutamol formulation via metered-dose inhaler alone, with plastic spacer, or with cardboard tube. [2001.04]

Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. [2001.02]

Equivalence of salbutamol 200 microg four times daily propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. Eastern European study group. [2000.06]

Equivalence of as-required salbutamol propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. German Study Group. [2000.06]

Proventil HFA prevents exercise-induced bronchoconstriction in children. [1999.12]

A controlled trial of chlorofluorocarbon-free triamcinolone acetonide inhalation aerosol in the treatment of adult patients with persistent asthma. Azmacort HFA Study Group. [1999.11]

Placebo-controlled, comparative study of the efficacy and safety of triamcinolone acetonide inhalation aerosol with the non-CFC propellant HFA-134a in patients with asthma. Azmacort HFA Clinical Study Group. [1999.10]

Protection against methacholine bronchoconstriction to assess relative potency of inhaled beta2-agonist. [1999.07]

Controlled trial of two formulations of cromolyn sodium in the treatment of asthmatic patients > or = 12 years of age. Intal Study Group. [1999.07]

Effect of electrostatic charge in plastic spacers on the lung delivery of HFA-salbutamol in children. [1999.03]

Evaluation of a non-chlorofluorocarbon formulation of cromolyn sodium (Intal) metered-dose inhaler versus the chlorofluorocarbon formulation in the treatment of adult patients with asthma: a controlled trial. [1998.01]

Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metered-dose inhaler in patients with asthma. [1996.03]

Acute safety of the CFC-free propellant HFA-134a from a pressurized metered dose inhaler. [1995]

Other research related to Ventolin HFA (Albuterol HFA)

COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study. [2013]

Repeat dosing of albuterol via metered-dose inhaler in infants with acute obstructive airway disease: a randomized controlled safety trial. [2010]

Albuterol metered dose inhaler performance under hyperbaric pressures. [2009.01]

Effects of extreme temperatures on drug delivery of albuterol sulfate hydrofluoroalkane inhalation aerosols. [2005.11.01]

Evaluation of particle size distribution of albuterol sulfate hydrofluoroalkane administered via metered-dose inhaler with and without valved holding chambers. [2005.01]

Effect of propellant on the pharmacokinetics and pharmacodynamics of inhaled albuterol in asthmatic subjects. [2003.03]

Albuterol delivery in a neonatal ventilated lung model: Nebulization versus chlorofluorocarbon- and hydrofluoroalkane-pressurized metered dose inhalers. [2001.03]

Combining a positive expiratory pressure device with a metered-dose inhaler reservoir system using chlorofluorocarbon albuterol and hydrofluoroalkane albuterol: effect on dose and particle size distributions. [2000.03]

Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications. [2000.02]

Drug form selection in albuterol-containing metered-dose inhaler formulations and its impact on chemical and physical stability. [1997.12]

Other possibly related research studies

Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. [2005.09]

Development and performance of a new hydrofluoroalkane (HFA 134a)-based metered dose inhaler (MDI) of salmeterol. [2005.04]

Aerosol profile extracted from spacers as a determinant of actual dose. [2004.12]

Medical aerosol propellant interference with infrared anaesthetic gas monitors. [2004.06]

Sub-micrometer particle production by pressurized metered dose inhalers. [2004.03]

Bioequivalence and other unresolved issues in generic drug substitution. [2003.11]

Electrostatic charge on spacer devices and salbutamol response in young children. [2003.08.11]

Prospective observational cohort safety study to monitor the introduction of a non-CFC formulation of salbutamol with HFA134a in England. [2003.02]

Performance of large- and small-volume valved holding chambers with a new combination long-term bronchodilator/anti-inflammatory formulation delivered by pressurized metered dose inhaler. [2002.01]

Novel nanoparticles for pulmonary drug administration. [2001]

Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica. [2001.06]

Delivery of HFA and CFC salbutamol from spacer devices used in infancy. [2001.07.03]

Characterisation of the aggregation behaviour in a salmeterol and fluticasone propionate inhalation aerosol system. [2001.06.19]

Factors affecting the efficiency of aerosol therapy with pressurised metered-dose inhalers through plastic spacers. [2001.01.12]

Pharmaceutical transition to non-CFC pressurized metered dose inhalers. [2000.06]

Hollow porous particles in metered dose inhalers. [2000.02]

In vitro comparison of salbutamol hydrofluoroalkane (Airomir) metered dose inhaler aerosols inhaled during pediatric tidal breathing from five valved holding chambers. [1999.01]

The pharmacokinetics of inhaled hydrofluoroalkane formulations. [1999.12]

Concepts of establishing clinical bioequivalence of chlorofluorocarbon and hydrofluoroalkane beta-agonists. [1999.12]

Reconciling in vitro and in vivo measurements of aerosol delivery from a metered-dose inhaler during mechanical ventilation and defining efficiency-enhancing factors. [1999.01]

Postmarketing surveillance study of a non-chlorofluorocarbon inhaler according to the safety assessment of marketed medicines guidelines. [1998.10.03]

Salbutamol delivery from a hydrofluoroalkane pressurized metered-dose inhaler in pediatric ventilator circuits: an in vitro study. [1998.01]

In vitro comparison of the amount of salbutamol available for inhalation from different formulations used with different spacer devices. [1997.06]

Systemic concentrations of salbutamol and HFA-134a after inhalation of salbutamol sulfate in a chlorofluorocarbon-free system. [1996.06]

Evaluation of efficacy and safety of flunisolide hydrofluoroalkane for the treatment of asthma. [2003.03]

Real-world assessment of a metered-dose inhaler with integrated dose counter. [2006.11]

The analysis and prediction of functional robustness of inhaler devices. [2007.03]

Fluticasone propionate/salmeterol hydrofluoroalkane via metered-dose inhaler with integrated dose counter: Performance and patient satisfaction. [2006.10]

A modified prescription-event monitoring study to assess the introduction of Seretide Evohaler in England: an example of studying risk monitoring in pharmacovigilance. [2007]

Novel propellant-driven inhalation formulations: engineering polar drug particles with surface-trapped hydrofluoroalkane-philes. [2008.02.05]

Investigations into the formulation of metered dose inhalers of salmeterol xinafoate and fluticasone propionate microcrystals. [2008.10]

Effects on small airway obstruction of long-term treatments with beclomethasone/formoterol hydrofluoroalkane (metered-dose inhaler) versus fluticasone/salmeterol (dry-powder inhaler) in asthma: a preliminary study. [2011]

Comparative lung bioavailability of fluticasone/salmeterol via a breath-actuated spacer and conventional plastic spacers. [2011]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017